The Journal of Infectious Diseases · 1992 · 84 citations · 13 references
PharmacyPharmacokineticsPharmacologyBioavailabilityPediatric Clinical PharmacologyPharmacokinetic ModelingAntiviral PharmacologyAntiviral TherapyPediatric PharmacokineticsPediatric Therapeutic Drug MonitoringAntiviral Therapeutic Drug MonitoringArea Under The Plasma Concentration-time CurveIntelligence QuotientPediatric Antiviral PharmacologyPharmacokinetic Absorption ParametersPharmacokinetic ParametersPlasma Concentration - Time ProfilePlasma Concentration-time Analysis
The pharmacokinetics of intravenous and oral 2',3'-dideoxyinosine (ddI) and the relationships between pharmacokinetic parameters and measures of response were studied in 48 human immunodeficiency virus-infected children. Disappearance of ddI from plasma after the intravenous dose was rapid and biexponential, with half-lives of 12 min and 1.0 h and a total clearance of 510 +/- 180 ml/min/m2. After oral administration, ddI absorption was limited and variable (mean bioavailability, 19% +/- 17%). A plasma ddI concentration-response relationship was observed for both decline in viral p24 antigen levels and improvement in intelligence quotient score. A limited sampling model was developed that accurately predicts the area under the ddI plasma concentration-time curve from one to three plasma samples. Although this pharmacokinetic study was done in children, the results also have relevance to adults and suggest that individualization of dose and schedule through therapeutic drug monitoring may be necessary to achieve optimal response.
13
Hiroaki Mitsuya, Kent J. Weinhold, P A Furman et al. · Proceedings of the National Academy of Sciences · 1985 · 1.9K citations · Full text
Hiroaki Mitsuya, S Broder · Proceedings of the National Academy of Sciences · 1986 · 1K citations · Full text
In Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-Dideoxyinosine
Robert Yarchoan, Hiroaki Mitsuya, Rose V. Thomas et al. · Science · 1989 · 425 citations